Guerbet Aims for Global Medical Imaging Leadership by Acquisition of Mallinckrodt’s CMDS Business

Guerbet (Paris, France) has announced a definitive agreement for the acquisition of the Contrast Media and Delivery Systems (CMDS) business of pharmaceutical giant Mallinckrodt (Chesterfield, Derbyshire, UK).

The acquisition gave Guerbet and the CMDS unit combined pro-forma sales of nearly EUR 800 million in 2014, a total of 2,500 employees worldwide, production sites in Ireland and in North America, and a global distribution network in nearly 65 countries. CMDS also includes various delivery systems and imaging solutions for X-ray cardiac and vascular imaging, X-ray scanners, Magnetic Resonance Imaging (MRI), and urological imaging systems. The CMDS business offers the contrast media Optiray and Optiject/Ultraject in X-ray, and syringe-based delivery systems. Guerbet provides the MRI contrast media Dotarem, hydraulic injection techniques for softbags.

Guerbet is acquiring 100% of the CMDS business in a transaction valued at about USD 270 million, and pending customary closing conditions is expected to close before the end of 2015. CMDS has a strong presence in the US and Guerbet in Europe. Guerbet is also planning to expand its presence in China, Russia and Turkey, and other markets with high growth potential.

Yves L’Epine, CEO of Guerbet, said, “This acquisition transforms and accelerates Guerbet’s future: it doubles our turnover, enables us to extend our geographical footprint and creates complementarities in both contrast media and imaging solutions and services. We will be very pleased to welcome Mallinckrodt’s CMDS colleagues to successfully and rapidly complete this integration together after the closing and create a new global leader in medical imaging.”

Related Links:
Guerbet
Mallinckrodt